Smith Group Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Smith Group Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-50	Closed	-$8K	–	401
2021 Q2	$8K	Hold	50	–	–	﹤0.01%	322
2021 Q1	$9K	Sell	50 -1,290	-96%	-$255K	﹤0.01%	274
2020 Q4	$294K	Hold	1,340	–	–	0.02%	161
2020 Q3	$223K	Buy	1,340 +410	+44%	+$56.1K	0.01%	165
2020 Q2	$106K	Sell	930 -20	-2%	-$1.94K	0.01%	192
2020 Q1	$73K	Hold	950	–	–	﹤0.01%	230
2019 Q4	$122K	Hold	950	–	–	0.01%	232
2019 Q3	$74K	Buy	+950	New	+$89.2K	﹤0.01%	253

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Smith Group Asset Management's MRTX Position: Q3 2021 in Review

Smith Group Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 50 shares — an estimated $8K sold.

Smith Group Asset Management first reported a position in MRTX in Q3 2019 and held it in 8 quarters. The position peaked at $294K in Q4 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

Smith Group Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Smith Group Asset Management sold 50 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $8K.
Smith Group Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
Smith Group Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $294K in Q4 2020.
238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Smith Group Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.